Vir Biotechnology (VIR) Long-Term Investments (2018 - 2026)
Vir Biotechnology (VIR) posted Long-Term Investments of $333.0 million for Q1 2026, up 5.85% sequentially from $314.6 million in Q4 2025, and up 52.64% YoY from $218.1 million in Q1 2025.
Vir Biotechnology (VIR) Long-Term Investments (2018 - 2026) Analysis & Trends
Vir Biotechnology has reported Long-Term Investments for 9 years, with the latest figure at $333.0 million in Q1 2026.
- Quarterly Long-Term Investments rose 52.64% year-over-year to $333.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $333.0 million (up 52.64% YoY) and the FY2025 annual result came in at $314.6 million, up 65.55% from the prior year.
- Long-Term Investments climbed to $333.0 million in Q1 2026 per VIR's latest filing, from $314.6 million in the prior quarter.
- Over five years, Long-Term Investments peaked at $359.7 million in Q1 2024 and troughed at $23.9 million in Q4 2022.
- A 5-year average of $180.2 million and a median of $190.0 million in 2024 frame the typical range for Long-Term Investments.
- The widest YoY moves for Long-Term Investments: up 1612.02% in 2022, down 88.12% in 2022.
- Over 5 years, Long-Term Investments stood at $23.9 million in 2022, then jumped by 339.98% to $105.3 million in 2023, then surged by 80.49% to $190.0 million in 2024, then jumped by 65.55% to $314.6 million in 2025, then advanced by 5.85% to $333.0 million in 2026.
- According to Business Quant data, Long-Term Investments over the past three periods registered $333.0 million, $314.6 million, and $304.2 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Long-Term Investments (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 5.79 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 9.83 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | - |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | - |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 372.10 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 22.17 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | - |
| 10 | Vir Biotechnology | 1.56 Bn | 1.56 Bn | 238.95 Mn | 475.02 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 475.02 Mn |
| Mar 31, 2026 | 332.97 Mn |
| Dec 31, 2025 | 314.58 Mn |
| Sep 30, 2025 | 304.21 Mn |
| Jun 30, 2025 | 286.10 Mn |
| Mar 31, 2025 | 218.14 Mn |
| Dec 31, 2024 | 190.02 Mn |
| Sep 30, 2024 | 271.50 Mn |
| Jun 30, 2024 | 279.99 Mn |
| Mar 31, 2024 | 359.72 Mn |
| Dec 31, 2023 | 105.28 Mn |
| Sep 30, 2023 | 39.62 Mn |
| Jun 30, 2023 | 52.36 Mn |
| Mar 31, 2023 | 49.19 Mn |
| Dec 31, 2022 | 23.93 Mn |
| Sep 30, 2022 | 34.10 Mn |
| Jun 30, 2022 | 97.59 Mn |
| Mar 31, 2022 | 103.54 Mn |
| Dec 31, 2021 | 201.39 Mn |
| Jun 30, 2021 | 5.70 Mn |